The 15-month study will test a biopolymer scaffold product, which was developed to treat patients with acute traumatic spinal cord injuries. Currently, no FDA-approved treatments exist or are in clinical trials for direct spinal cord intervention, according to the release.
More Articles on Devices:
Stryker Names William Jellison CFO
Biomet Gains Exclusive Distribution Rights to OPM OsteoFab Implants
13 Spine Devices Receive FDA 510(k) Clearance in March
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
